Is Solid Biosciences Inc. (SLDB) a Buy, Sell, or Hold?
Solid Biosciences Inc.
NASDAQ:SLDB
$9.63 USD
-$0.09 (-0.93%)
- Volume
- 921.31K
- Average Volume
- 1.7M
- Market Capitalization
- $750.28M
- P/E Ratio
- -4.94
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $11.45
- Year Low
- $3.79
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $13.10
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Alexander G. Cumbo |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SLDB |
| CUSIP | 83422E204 |
| CIK | 0001707502 |
| Web | https://www.solidbio.com |
| Phone | 617 337 4680 |
| Currency | USD |
| Employees | 121 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.06 |
| Payout Ratio | 0.00 |
| Current Ratio | 13.10 |
| Quick Ratio | 13.10 |
| Cash Ratio | 9.83 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.57 |
| Price / Cash Flow | -4.34 |
| Price / Book | 2.83 |
Price Target and Rating
| Average Stock Price Forecast | $17.00 |
| High Stock Price Forecast | $18.00 |
| Low Stock Price Forecast | $16.00 |
| Forecast Upside/Downside | -43.35% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 21 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.99 |
| Trailing P/E Ratio | -4.94 |
| PEG Ratio | -0.13 |
| P/E Growth | -0.13 |
| Net Income | $-174.32M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -74.45% |
| Return on Assets | -45.35% |
Financials Score
| AltmanZ Score | 5.50 |
| Piotroski Score | 2.00 |
| Working Capital | 366.5M |
| Total Assets | 422.89M |
| Ebit | -191.72M |
| Market Cap | 757.29M |
| Total Liabilities | 48.76M |
Poll Results
About Solid Biosciences Inc. (NASDAQ:SLDB) Stock
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a colla ... boration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Solid Biosciences: The Bull Case Is No Longer Just Duchenne
2026-07-02 07:30:00
Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB's $380.7M cash position funds operations into 2028, supporting high-cost Phase 3 SGT-003 trials and multiple pipeline programs without near-term dilution risk. SGT-003's Phase 1/2 data show strong microdystrophin expression and safety, while additional programs in Friedreich's ataxia and CPVT expand addressable markets.
2026-06-08 19:08:30
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 16:05:00
CHARLESTOWN, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units ("RSUs") to one newly hired employee.
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 16:05:00
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units (“RSUs”) to one newly hired employee.
Solid Biosciences to Participate at Upcoming Investor Conferences
2026-06-01 08:00:00
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Jefferies Global Healthcare Conference Bo Cumbo, President and CEO, will be presenting on Wednesday, June 3, 2026, at 7:35 a.m.
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 16:08:00
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program's global development -
2026-05-07 08:00:00
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global regulatory authorizations for SGT-003 -
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 16:05:00
CHARLESTOWN, Mass. , May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,070 restricted stock units ("RSUs") to one newly hired employee.
Frequently Asked Questions
-
What is the current Solid Biosciences Inc. (SLDB) stock price?
-
Solid Biosciences Inc.(NASDAQ:SLDB) stock price is $9.63 in the last trading session. During the trading session, SLDB stock reached the peak price of $11.45 while $3.79 was the lowest point it dropped to. The percentage change in SLDB stock occurred in the recent session was --0.93% while the dollar amount for the price change in SLDB stock was -$-0.09.
-
SLDB's industry and sector of operation?
-
The NASDAQ listed SLDB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SLDB?
-
Nicole Anderson | Senior Director of Investor Relations & Corporate Communications
Ian F. Smith | Executive Chair
Ilan Ganot | Co-founder, Strategic Advisor to the Chief Executive Officer & Director
David Tyronne Howton Jr. | Chief Operating Officer & Secretary
Annie Ganot | Co-Founder & Vice President of Patient Advocacy -
How many employees does SLDB have?
-
Number of SLDB employees currently stands at 121. SLDB operates from 141 Portland Street, Cambridge, MA 02139, US.
-
Link for SLDB official website?
-
Official Website of SLDB is: https://www.solidbio.com
-
How do I contact SLDB?
-
SLDB could be contacted at phone #617 337 4680 and can also be accessed through its website. SLDB operates from 141 Portland Street, Cambridge, MA 02139, US.
-
How many shares of SLDB are traded daily?
-
The average number of SLDB shares traded daily for last 3 months was 1.7M.
-
What is the market cap of SLDB currently?
-
The market value of SLDB currently stands at $750.28M with its latest stock price at $9.63